Kozato A, Fox GWC, Yong PC, et al. - Increased risk of venous thromboembolism (VTE) has been reported in correlation with both surgery and exogenous estrogen use. However, researchers sought to determine if the surgery-associated risk is exacerbateb by estrogen hormone therapy (HT) among transgender and gender non-binary (TGNB) individuals. They conducted a single-center retrospective chart review on 919 TGNB patients who underwent 1,858 surgical procedures representing 1,396 unique cases. Of these 407 cases were transfeminine patients undergoing primary vaginoplasty. One of all cases presented with VTE, from the cohort of transfeminine patients whose estrogen HT was suspended prior to surgery. Overall findings from this large, homogenously treated cohort of TGNB patients suggest that perioperative VTE was not a significant risk; this was noted independent of whether or not hormone therapy was suspended prior to surgery.